MedPath

Vicagrel

Generic Name
Vicagrel
Drug Type
Small Molecule
Chemical Formula
C18H18ClNO4S
CAS Number
1314081-53-2
Unique Ingredient Identifier
8A63K3TN0U
Background

Vicagrel is under investigation in clinical trial NCT03599284 (The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel).

Indication

预防和治疗因血小板聚集状态引起的心、脑及其他动脉的循环障碍疾病。

Clinical Trials
Related News

Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)

Phase 3
Recruiting
Conditions
Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
Interventions
First Posted Date
2024-08-29
Last Posted Date
2024-10-01
Lead Sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Target Recruit Count
1000
Registration Number
NCT06577519
Locations
🇨🇳

General Hospital of Northern Theater Command of Chinese PLA, Shenyang, Liaoning, China

Assessment of the Effect of Omeprazole on Vicagrel in Healthy Subjects

Phase 1
Recruiting
Conditions
Healthy Subjects
Interventions
First Posted Date
2022-12-14
Last Posted Date
2023-01-31
Lead Sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Target Recruit Count
20
Registration Number
NCT05651074
Locations
🇨🇳

Phase I Clinical Research Center of The First Hospital of Jilin University, Chang chun, Jilin, China

PK/PD Study of Vicagrel and Clopidogrel in Healthy Subjects With Different CYP2C19 Metabolizers

Phase 1
Completed
Conditions
Acute Coronary Syndrome
Interventions
First Posted Date
2021-12-17
Last Posted Date
2023-11-03
Lead Sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Target Recruit Count
128
Registration Number
NCT05162053
Locations
🇺🇸

Altasciences, Kansas City, Kansas City, Missouri, United States

🇺🇸

Altasciences Clinical, Los Angeles, Los Angeles, California, United States

🇨🇳

Phase I Clinical Research Center of The First Hospital of Jilin University, Changchun, Jilin, China

A Clinical Trial to Evaluate the Effect of Food on PK and PD of Vicagrel Capsules in Healthy Adult Subjects

Phase 1
Completed
Conditions
Acute Coronary Syndrome
Interventions
First Posted Date
2021-06-09
Last Posted Date
2021-11-01
Lead Sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Target Recruit Count
24
Registration Number
NCT04919551
Locations
🇨🇳

The First Hospital of Jilin University, Changchun, Jilin, China

Pharmacokinetics and Pharmacodynamics of Vicagrel in Healthy Adult Subjects of Different CYP2C19

Phase 1
Completed
Conditions
Healthy Subjects
PK/PD
Interventions
First Posted Date
2019-05-08
Last Posted Date
2019-09-19
Lead Sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Target Recruit Count
50
Registration Number
NCT03942458
Locations
🇨🇳

The First Hospital of Jilin University, Chang chun, Jilin, China

The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel

Phase 2
Completed
Conditions
Coronary Artery Disease
Platelet Aggregation Inhibitors
Percutaneous Coronary Intervention
Interventions
First Posted Date
2018-07-26
Last Posted Date
2019-09-23
Lead Sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Target Recruit Count
279
Registration Number
NCT03599284
Locations
🇨🇳

Second Xiangya Hospital of Central South University, Changsha, Hunan, China

🇨🇳

Qinghai Provincial People's Hospital, Xining, Qinghai, China

🇨🇳

Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China

and more 24 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy